Santhera Targets New Indication with its Lead Compound
SNT-MC17 (idebenone) enters Phase IIa study in Duchenne muscular dystrophy
The Phase IIa DMD study is a double-blind, randomised, placebo-controlled trial which aims to assess the efficacy of SNT-MC17 in 10 to 16 year old males with cardiac dysfunction associated with DMD. The primary endpoint is to evaluate cardiac function improvement in DMD patients after one year of treatment. The effect of SNT-MC17 on muscle strength in the limbs and respiratory muscles will also be assessed as secondary endpoints. This study will take place at the University of Leuven in Belgium, and will enroll a total of 21 patients. The principal investigator of this study is Prof. Gunnar Buyse, a distinguished physician in the field of neuromuscular disease.
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.